Scintix BgRT
Tumors in Lung and Bone
Key Facts
About RefleXion Medical
RefleXion Medical is pioneering a transformative approach to radiation therapy with its proprietary Scintix biology-guided radiotherapy system. This technology leverages PET signals from injected radiotracers to detect and continuously track tumors, allowing for automated, high-precision radiation delivery that can adapt to tumor motion and treat multiple metastatic sites simultaneously. Founded in 2009 and based in Hayward, California, the company represents a significant convergence of radiotherapy, diagnostic imaging, and radiopharmaceuticals. Its platform has the potential to shift radiation oncology from a primarily anatomic-based, pre-planned modality to a real-time, biology-driven treatment, particularly for patients with metastatic disease.
View full company profileAbout RefleXion Medical
RefleXion Medical is pioneering a transformative approach to radiation therapy with its proprietary Scintix biology-guided radiotherapy system. This technology leverages PET signals from injected radiotracers to detect and continuously track tumors, allowing for automated, high-precision radiation delivery that can adapt to tumor motion and treat multiple metastatic sites simultaneously. Founded in 2009 and based in Hayward, California, the company represents a significant convergence of radiotherapy, diagnostic imaging, and radiopharmaceuticals. Its platform has the potential to shift radiation oncology from a primarily anatomic-based, pre-planned modality to a real-time, biology-driven treatment, particularly for patients with metastatic disease.
View full company profileAbout RefleXion Medical
RefleXion Medical is pioneering a transformative approach to radiation therapy with its proprietary Scintix biology-guided radiotherapy system. This technology leverages PET signals from injected radiotracers to detect and continuously track tumors, allowing for automated, high-precision radiation delivery that can adapt to tumor motion and treat multiple metastatic sites simultaneously. Founded in 2009 and based in Hayward, California, the company represents a significant convergence of radiotherapy, diagnostic imaging, and radiopharmaceuticals. Its platform has the potential to shift radiation oncology from a primarily anatomic-based, pre-planned modality to a real-time, biology-driven treatment, particularly for patients with metastatic disease.
View full company profile